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Background-—In patients with mechanical heart valves, cerebral susceptibility-weighted imaging (SWI) lesions on magnetic
resonance imaging, postulated to be caused by degenerative metallic abrasion, are frequently referred to as valve abrasion. It
remains unclear whether valve implantation not requiring cardiopulmonary bypass or biological heart valves also shows those
lesions.
Methods and Results-—Two blinded readers rated SWI lesions and cerebral amyloid angiopathy probability according to
established criteria on brain magnetic resonance imaging pre- and postinterventionally. We assessed the association between
valve type/cardiopulmonary bypass use and SWI lesion count on the ﬁrst postinterventional scan using multivariable logistic
regression. On postinterventional magnetic resonance imaging, 57/58 (98%) patients with mechanical heart valves had at least 1
and 46/58 (79%) 3 or more SWI lesions, while 92/97 (95%) patients with biological heart valves had at least 1 and 72/97 (74%) 3
or more SWI lesions. On multivariate analysis, duration of cardiopulmonary bypass during implantation signiﬁcantly increased the
odds of having SWI lesions on the ﬁrst postinterventional magnetic resonance imaging (b per 10 minutes 0.498; 95% CI, 0.116–
0.880; P=0.011), whereas valve type showed no signiﬁcant association (P=0.338). Thirty-seven of 155 (23.9%) patients fulﬁlled the
criteria of possible/probable cerebral amyloid angiopathy.
Conclusions-—SWI lesions in patients with artiﬁcial heart valves evolve around the time point of valve implantation and the majority
of patients had multiple lesions. The missing association with the valve type weakens the hypothesis of degenerative metallic
abrasion and highlights cardiopulmonary bypass as the main risk factor for SWI occurrence. SWI lesions associated with cardiac
procedures can mimic cerebral amyloid angiopathy. Further research needs to clarify whether those lesions are associated with
intracranial hemorrhage after intravenous thrombolysis or anticoagulation. ( J Am Heart Assoc. 2019;8:e012814. DOI: 10.1161/
JAHA.119.012814.)
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S usceptibility-weighted magnetic resonance imaging (SWI)or gradient echo magnetic resonance imaging are
sensitive imaging techniques to detect cerebral microbleeds
(CMBs) by utilizing the magnetic ﬁeld inhomogeneity of
deoxygenated hemoglobin.1–3 CMBs are associated with
chronic hypertension, other vascular risk factors, dementia,
cerebral amyloid angiopathy (CAA), diffuse axonal injury, and
also with normal aging.4 Unfortunately, the technique is not
speciﬁc and there is a broad differential diagnosis of SWI
lesions including foreign materials such as metals or ceramics,
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vascular malformations, intracranial calciﬁcations, brain
tumors, air emboli, prior use of extracorporeal membrane
oxygenation, or prolonged intensive care unit stay.4–8
In patients with mechanical heart valves (mHV), SWI
lesions have been described that were originally suspected to
be caused by small metallic emboli by degenerative metallic
abrasion of the valve structure.9–11 Although older mHV had a
metallic shackle, modern mHV consist of pyrolytic carbon
except the noble metal stent structure in some models or the
annulus, which may be made up of titanium covered by a
Dacron textile. This change of composition calls into question
the metallic abrasion hypothesis. Nevertheless, carbon abra-
sion also might induce SWI artifacts.12
Furthermore, cardiopulmonary bypass (CPB) during valve
implantation was also shown to be associated with postin-
terventional SWI lesions.5,13–15 No data are available on
patients receiving biological heart valves (bHV). Therefore, it is
unclear whether patients with transcatheter aortic valve
implantation who do not require CPB or patients with bHV
may also show those SWI lesions. In conclusion, SWI lesions
are seen in patients with any artiﬁcial heart valve (aHV) but
their occurrence, cause, and signiﬁcance are not well
understood.
Patients with aHV require oral anticoagulation (OAC) in the
case of mHV and platelet aggregation inhibitors in the case of
bHV to prevent ischemic stroke and systemic emboli. However,
each group may require additional platelet aggregation
inhibitors or OAC for other medical reasons (eg, atrial ﬁbrilla-
tion, low left ventricular ejection fraction, or coronary stenting).
When multiple SWI lesions are detected in a certain distribution
and interpreted as CMBs, CAA should be suspected,16 since it is
a disease that carries a very high risk of intracranial hemorrhage
(ICH). Hence, in such patients there is a therapeutic balancing
act between the risk of ischemic stroke and ICH. Additionally,
CMBs are increasingly considered in guiding treatment deci-
sions for intravenous thrombolysis17 or anticoagulation,18 and
such treatments might be withheld from patients with aHV
because of the presence of SWI lesions. It is therefore important
to know whether multiple SWI lesions in patients with aHV are
true CMBs suggesting increased ICH risk or simply an
epiphenomenon caused by either the material or the intracar-
diac procedure.
With this retrospective analysis, we want to provide a
temporal and topical description of SWI lesions in patients
with aHV and possibly aid in differentiating radiologically
between CAA and the lesions seen with aHV.
Methods
For this study, approval of the cantonal ethics committee was
obtained (KEK 2018-01300) and no informed consent was
required according to local legislation. The data that support
the ﬁndings of this study are available from the corresponding
author upon reasonable request after clearance by the
responsible ethics committee.
We identiﬁed all cerebral magnetic resonance imaging
(MRI) examinations including SWI or gradient echo imaging
sequences of patients with aHV by using the search terms
“*klappe” (valve), “AKE” (aortic valve replacement), “MKE”
(mitral valve replacement), and “Klappenabrieb” (valve abra-
sion) in the radiological information system of our tertiary
university department of diagnostic neuroradiology. Since SWI
and gradient echo imaging sequences have been used since
2005, we limited the date range to MRI examinations after
January 1, 2005 until August 2018. We included only patients
who signed the declaration of consent for the use of biological
material and health-related data for medical research.
We excluded patients with diagnoses that might lead to
confounding SWI lesions including ischemic stroke with
hemorrhagic transformation, intracranial hemorrhage, SWI
lesions associated with septic infarctions caused by infectious
endocarditis, cerebral surgery, interventions or radiotherapy,
Clinical Perspective
What Is New?
• Susceptibility-weighted imaging (SWI) lesions are a very
frequent ﬁnding in neurologically symptomatic patients with
mechanical and biological heart valves, and most patients
have multiple lesions.
• SWI lesions were signiﬁcantly associated with cardiopul-
monary bypass time during implantation, but not mechanical
valve type.
• SWI lesions evolved around the valve implantation and
remained stable thereafter in most patients, and SWI lesions
associated with heart valves can mimic cerebral amyloid
angiopathy, but superﬁcial siderosis is seldom present in
those patients.
What Are the Clinical Implications?
• The hypothesis of degenerative metallic abrasion is weak-
ened, and our ﬁndings highlight cardiopulmonary bypass as
the main risk factor for SWI lesion occurrence.
• As SWI lesions (cerebral microbleeds) are increasingly
considered in guiding treatment decisions for intravenous
thrombolysis or anticoagulation, we hence question whether
the SWI lesions seen with cardiopulmonary bypass share the
same pathophysiological features and long-term bleeding
risk as cerebral microbleeds seen with cerebral amyloid
angiopathy or classical vascular risk factors.
• Autopsy studies are warranted to identify the true patho-
physiological cause of SWI lesions in patients with car-
diopulmonary bypass exposure.
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cerebral tumors, vascular malformations, cerebral trauma,
moyamoya disease, cardiac myxoma, Pompe disease, or
cerebral vasculitis.
Variables and Image Analysis
Biometrical data of patients included age, sex, body mass
index, and renal function (glomerular ﬁltration rate mL/min) at
the time point of the ﬁrst postinterventional MRI. Valve
replacement was categorized in mechanical aortic valve
replacement (AVR), biological aortic valve replacement,
mechanical mitral valve replacement, biological mitral valve
replacement, combination of mechanical aortic valve replace-
ment and mitral valve replacement, combination of biological
aortic valve replacement and mitral valve replacement, and
other types of valve replacement. Patients with re-implanta-
tions of bHV after a mHV were considered mHV patients.
Medication parameters included use of acetylsalicylic acid,
vitamin-K antagonists, non-vitamin-K antagonist oral antico-
agulants, and statin therapy at the time point of the ﬁrst
postinterventional MRI.
In-house imaging studies were performed using 1.5 T and
3 T Siemens scanners (Magnetom Avanto, Aera, Magnetom
Verio, Siemens Medical Solution, Erlangen, Germany) with 12-
channel head coil. For the 1.5 T MRI the following SWI
parameters were used: repetition time 49 ms, echo time
40 ms, number of averages 1, ﬁeld of view read 230 mm,
ﬁeld of view phase 81.3%, voxel size 1.190.991.8 mm, ﬂip
angle 15°. For 3 T: repetition time 28 ms, echo time 20 ms,
number of averages 1, ﬁeld of view read 230 mm, ﬁeld of view
phase 75%, voxel size 1.290.7191.8 mm, ﬂip angle 15°.
Slice thickness of the maximum-intensity-projection of the
SWI is between 12 and 16 mm.
Two readers, 1 neuroradiology fellow (P.B.) and 1 fellow in
stroke neurology (T.R.M.) blinded to patients’ valve status,
reviewed the number and location of SWI lesions. Additionally,
they assessed the presence of cortical superﬁcial siderosis.
We used the rating of the neuroradiology fellow for ﬁnal
analysis. The ratings of the neurology fellow were used to
assess interrater agreement.
SWI lesions were deﬁned according to the criteria
proposed by Greenberg et al4 as round or ovoid black lesions
of >1 to 10 mm size with at least half of the lesion
surrounded by brain parenchyma and clearly distinct from iron
or calcium deposits in typical regions, bone or vessel ﬂow
voids. We counted SWI lesions in the following regions (lobar
cortico-subcortical, deep white matter, basal ganglia, pons
and midbrain, cerebellar). Lobar cortico-subcortical regions
were deﬁned as <10 mm from the brain surface. In each
region, we counted lesions up to a maximum of 20 per region.
We rated CAA probability using recent modiﬁcations of the
Boston Criteria.19
Statistical Analysis
We made univariate comparisons between patients with
biological and mechanical aHV as well as between patients
implanted on or without CPB using standard statistical
measures (Fisher exact test for categorical variables, Mann–
Whitney U test for nonnormally continuous or ordinally scaled
variables, and Welsch t test for independent normally
distributed data). We did unadjusted analysis using Spear-
mans Rho correlation coefﬁcient. We assessed interrater
agreement for the number of SWI lesions using limits of
agreement in the Bland-Altmann plot. A difference of >5
lesions was considered clinically important. Therefore, we
prespeciﬁed 5 lesions as the maximum allowed difference.
We assessed the association between mechanical valve
type as well as CPB duration (per 10-minute increase) and
the odds of the number of SWI lesions on the ﬁrst
postinterventional MRI scan using multivariable logistic
regression with adjustments for the following prespeciﬁed
confounders: age (continuous), sex (categorical), body mass
index (continuous), days in intensive care unit after implan-
tation (continuous), estimated glomerular ﬁltration rate
(continuous), ascending aorta replacement (categorical),
deep hypothermic circulatory arrest (DHCA, categorical),
persisting foramen ovale/atrial septal defect closure (cate-
gorical), hypertension (categorical), diabetes mellitus (cate-
gorical), smoking (categorical), use of acetylsalicylic acid,
clopidogrel, any OAC or statin (categorical), and Tesla of MRI
(categorical 1.5 versus 3).
For follow-up examinations, SWI lesion difference and time
in months from ﬁrst postinterventional to last available scan
was calculated and the relevant difference was deﬁned as an
alteration that exceeded the 95% CI of the interrater
variability.
Results
Interrater Agreement
Bland-Altmann plot for the interrater agreement showed that
the limits of agreement (95% of all ratings) were from 3.5 to
+6.0, within the prespeciﬁed maximum allowed difference of
5, indicating reasonable agreement with few clinically
important differences (Figure 1). There was signiﬁcant pro-
portional bias; however, its magnitude was very small
(b=0.077, P<0.001).
Cohort Characterization
The baseline parameters of our cohort are presented in
Table 1 (stratiﬁed for valve type and CPB use in Tables S1 and
S2). A total of 155 patients with a median age of 71 years
(interquartile range 58–77) were included. Roughly two thirds
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received a biological and one third a mechanical valve type.
About half of the patients were orally anticoagulated, whereas
the other half were taking antiplatelet agents. The risk factors
and extent of white matter lesions correspond to an
intermediate cardiovascular risk proﬁle.
Preinterventional Scan
For 25 patients, preinterventional MRI scans were available
with a median time before implantation of 12 months
(interquartile range 1–35). Of those, 13 (52%) had no SWI
lesion before valve implantation and a further 7 (28%) had 1
SWI lesion.
First Postinterventional Scan
Indications for postinterventional MRI examinations were an
acute neurological deﬁcit (57.4%), control of vascular pathol-
ogy, eg, carotid stenosis (12.8%), epileptic seizure (6.1%),
cognitive problems (4.7%), headache (2.7%), disorders of
consciousness (2.7%), suspected tumor or metastasis (2.0%),
movement anomalies (2.0%), vertigo (2.0%), suspected menin-
goencephalitis (1.4%), and others (6.1%). Location of SWI
lesions was unrelated to acute lesions, if present. The median
time between valve implantation and ﬁrst postinterventional
MRI was 17 months (interquartile range 0–76).
The increase in SWI lesions from the preinterventional to
the ﬁrst postinterventional MRI scan is presented in Table 2.
Patients receiving a mHV had a more pronounced increase
than patients receiving a bHV (P<0.001). Seven of 25 patients
underwent transcatheter aortic valve implantation and 18/25
underwent open surgery. Four patients had no change in SWI
lesions, all of which received bHV and 3 of 4 without use of
CPB (Figure 2).
In patients with mHV, 97% (56/58) had at least 1, 87%
(50/58) at least 2, and 79% (46/58) 3 or more SWI lesions
(Figure S1A). In patients with bHV, 95% (92/97) had at least
1, 85% (82/97) at least 2, and 76% (72/97) 3 or more SWI
lesions (Figure S1B).
On unadjusted analysis, signiﬁcant differences in postin-
terventional SWI lesion count were observed for CPB versus
no CPB use (median 7 versus 1.5, P<0.001, Figure S2), mHV
versus bHV (median 9 versus 5, P=0.001, Figure S3),
ascending aortic replacement versus no replacement (median
10 versus 5, P<0.001), vitamin-K antagonists versus no
vitamin-K antagonists medication (median 8 versus 5,
P=0.042), non-vitamin-K antagonist oral anticoagulants versus
no non-vitamin-K antagonist oral anticoagulants medication
(median 7 versus 2.5, P=0.035), and DHCA versus no DHCA
(8 versus 6, P=0.019). Furthermore, age (rs=0.293,
P<0.001), body mass index (rs=0.247, P=0.002), duration
of CPB use (rs=0.495, P<0.001, Figure S4), duration of DHCA
use (rs=0.225, P=0.008), and days of intensive care unit stay
(rs=0.357, P<0.001) were signiﬁcantly correlated with postin-
terventional SWI lesion count.
According to multivariable linear logistic regression anal-
ysis adjusting for prespeciﬁed confounders outlined in the
Methods section, duration of CPB (b per 10 minutes 0.498;
95% CI, 0.116–0.880; P=0.011) was associated with a higher
SWI lesion count on the ﬁrst postinterventional MRI. No
Figure 1. Bland-Altmann plot for the interrater agreement. The red line indicates the mean difference of
all ratings and the green lines indicate the limits of agreement (95% of all ratings). Limits of agreement were
from 3.5 to +6.0, within the prespeciﬁed maximum allowed difference of 5, indicating reasonable
agreement with few clinically important differences. SWI indicates susceptibility-weighted imaging.
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statistical signiﬁcant association was found for mechanical
valve type (P=0.338).
Of the prespeciﬁed confounders, only age per year
increase (b=0.326; 95% CI, 0.566 to 0.0872; P=0.008)
was associated with a lower SWI lesion count, whereas no
statistically signiﬁcant associations were found for duration of
intensive care unit stay (P=0.483), anticoagulation use
(0.552), statin use (P=0.535), higher body mass index per
kg/m2 (P=0.162), and DHCA (P=0.476). On sensitivity
analyses considering only patients on-pump, CPB per 10 min-
utes remained a signiﬁcant factor related to SWI lesion
number on the ﬁrst postoperative MRI scan (b=0.576; 95% CI,
0.130–1.021; P=0.012). In a post hoc analysis, neither
selective antegrade cerebral perfusion (P=0.575) nor the
lowest temperature during CPB was associated with postop-
erative SWI lesion count in bivariate correlation (P=0.360).
There were 6.1% of patients who fulﬁlled the criteria of
“possible CAA” and a further 16.4% the criteria of “probable
CAA” according to the modiﬁed Boston Criteria on the ﬁrst
postinterventional scan, with only 3.6% of patients showing
superﬁcial siderosis. Patients with bHV were more likely to
fulﬁll CAA criteria, with 5 (5.2%) fulﬁlling possible and 23
(23.7%) probable CAA criteria versus 5 (8.6%) fulﬁlling
possible and 4 (6.9%) probable CAA in patients with mHV
(v2 P=0.025). In many patients, additional very small SWI
lesions <1 mm were present that were not accounted for in
the analysis because they did not fulﬁll the established criteria
for CMBs.4 The type of valve replacements is presented in
Figure S5 and location of SWI lesions is presented in Figures
S6 and S7.
Further Follow-Up MRI Scans
Follow-up MRI examinations were available for 56 patients
with a median time after ﬁrst postinterventional scan of
6 months (interquartile range 1–20). In 91.1% (51/56) of
those, there was no further increase in SWI lesions (Figure 2).
In those 5 patients with a warranted increase of SWI lesions, 3
Table 1. Baseline Characteristics of All Patients
Clinical Items N=155
Age, y 71 (IQR 58–77)
Female sex 44 (28.4%)
BMI, kg/m2 27.1 (IQR 24.3–30.2)
Risk factors
Hypertension 115 (75.2%)
Smoking 44 (28.8%)
Diabetes mellitus 32 (20.9%)
eGFR, mL/min 74 (IQR 54–90)
Surgery
Biological valve 97 (62.6%)
Mechanical valve 58 (37.4%)
Ascending aorta replacement 34 (21.9%)
PFO/ASD closure 5 (3.2%)
Days in ICU 1 (IQR 1–2)
CPB 137 (88.4%)
TAVI 18 (11.6%)
Deep hypothermic circulatory arrest 27 (18.9%)
Deep hypothermic circulatory arrest, min 19 (IQR 14–28)
Medication
ASA 88 (56.8%)
Clopidogrel 15 (9.7%)
Dual antiplatelet 4 (2.6%)
VKA 73 (47.1%)
NOAC 12 (7.7%)
OAC, any 85 (54.8%)
Statin, any 79 (51.3%)
Imaging
1.5 T 119 (78.3%)
3 T 33 (21.7%)
Fazekas Score
0 31 (20.3%)
1 81 (52.9%)
2 32 (20.9%)
3 9 (5.9%)
ASA indicates acetylic salicylic acid; ASD, atrial septal defect; BMI, body mass index
(kg/m2); CPB, cardiopulmonary bypass; eGFR, estimated glomerular ﬁltration rate
(mL/min); ICU, intensive care unit; IQR, interquartile range; NOAC, non-vitamin K
antagonist oral anticoagulants; OAC, oral anticoagulation; PFO, persisting foramen ovale;
TAVI, transcatheter aortic valve replacement; VKA, vitamin K antagonists.
Table 2. Change of Pre- to First Postinterventional Scan
According to Valve Type and CPB Use
SWI Lesion
Count Preinterventional Postinterventional
Change (n=25 With
Preinterventional
MRI)
Biological
valve
0.5 (0–1.25),
n=18
5 (2–9), n=97 +2 (1–4)
Mechanical
valve
0 (0–1), n=7 9 (4–20), n=58 +9 (7–10)
Any valve
(N=25)
0 (0–1), n=25 7 (3–12),
n=155
+4 (1–7)
CPB yes 0 (0–1.25),
n=18
7 (3–13.5),
n=137
+5.5 (2.75–8.25)
CPB no 1 (0–1), n=7 1.5 (1–4), n=18 +1 (0–2)
CPB indicates cardiopulmonary bypass; MRI, magnetic resonance imaging; SWI,
susceptibility-weighted imaging.
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had a bHV and all had other medical conditions possibly
explaining CMBs formation on follow-up imaging: 1 had
chronic aortic dissection with complicated intensive care unit
stay, 1 had a second surgery with CPB use, 1 had heparin-
induced thrombocytopenia, and 2 had possible clinical CAA
with recurrent cerebral acute ischemic events and cognitive
decline. In 7 patients who had no SWI lesion on ﬁrst
postinterventional scan, 3 had a follow-up image available
with 2 having 1 incident SWI lesion (median follow-up
2.5 years after ﬁrst MRI).
Discussion
This retrospective analysis of cerebral MRI scans in aHV
patients showed the following main ﬁndings: (1) In our cohort
of patients with aHV, the frequency of postinterventional SWI
lesions was very high irrespective of the type of valve that was
implanted (mechanical or biological valve), with the vast
majority of patients having multiple lesions. (2) The main risk
factor for SWI lesions was duration of CPB. (3) SWI lesions
associated with aHV may imitate CAA. (4) SWI lesions evolved
around the valve implantation and remained stable thereafter
in most patients.
The hypothesis of degenerative metallic abrasion of the
valve structure was postulated almost 20 years ago based on
only a few cases without pathological proof and limited
knowledge about the differential diagnosis of SWI lesions.9–11
In population-based studies, CMBs were detected in 5% to
35% of older individuals,20,21 but only up to 20% of individuals
showed multiple CMBs. With about 280 000 prosthetic valves
implanted each year and virtually all modern aHV considered
safe in MRI scans at ﬁeld strengths of up to 1.5 T, MRI will be
increasingly used in patients with aHV.22–24
Cardiopulmonary Bypass
Our ﬁndings regarding the inﬂuence of CPB are in accordance
with a recent prospective study of 75 patients undergoing on-
pump cardiac surgery showing that 76% had new SWI lesions
after the surgery.15 In this study, new CMBs were associated
with longer CPB times (odds ratio, 1.02 per minute; 95% CI,
1.00–1.05; P=0.04). Hence, we can conﬁrm the association of
CPB time as a relevant factor to SWI lesion genesis. In a
second study, gradient echo imaging lesions have been
analyzed prospectively in patients requiring valve surgery and
were found in 63% (12/19) of patients postoperatively.25 The
slightly lower rate of postoperative SWI lesions might be
because of lower sensitivity of gradient echo imaging as
compared with SWI sequences. Another study showed that
SWI lesions occur after coronary bypass surgery, but only
when CPB was used and with a similar frequency.13 It is
known that the CPB circuit may contain air emboli and/or
microparticles, which may also be detected using transcranial
Doppler ultrasound.26 However, it is rather unlikely that the
postoperative SWI lesions are mainly caused by air since they
were also detectable 6 weeks after surgery.15
Figure 2. Double logarithmic plot of SWI lesion count of ﬁrst postinterventional MRI scan in relation to
valve implantation time in months. There was a median increase in SWI lesions of 4 (IQR 1–7) from the
preinterventional to the ﬁrst postinterventional MRI scan (bHV 2, IQR 1–4; mHV 9, IQR 7–10). bHV
indicates biological heart valves; IQR, interquartile range; mHV, mechanical heart valves; MRI, magnetic
resonance imaging; SWI, susceptibility-weighted imaging.
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Embolic and hemodynamic ischemic brain infarcts are a
well-known complication of valve surgery,27 and secondary
hemorrhagic transformation may thus explain occurrence of
SWI lesions after valve implantation procedures.28 However,
the SWI lesions observed in our study were not associated
with diffusion-weighted imaging lesions when brain MRI was
performed shortly after the intervention. Furthermore, the
frequency of SWI lesions in our study was higher than the
known rates for diffusion-weighted imaging lesions after valve
surgery and the rate of hemorrhagic transformation of
ischemic stroke is usually only at 20% to 30%.28,29 Lastly,
the SWI lesions observed in our study were singular spots and
did not show the classical phenotypes of hemorrhagic
transformation. Hence, we do not think that secondary
hemorrhagic transformation of embolic infarcts (fully) explains
the SWI lesions associated with CPB use.
While known complications of DHCA are postischemic
hypothermia, impaired autoregulatory mechanisms, and dam-
age to the blood–brain barrier,30 we found no signiﬁcant
association with postoperative SWI lesion count after adjust-
ing for CPB time on multivariate analysis.
Valve Type
In our study, the prevalence of postinterventional SWI lesions
in patients with aHV was very high. Patients with mHV had a
higher lesion count than patients with bHV; however, this is
likely because mHV is a confounder related to CPB since valve
type was not a signiﬁcant factor on multivariate analysis. Our
ﬁndings are in line with a recent prospective study with pre-
and postinterventional MRI scans, which showed that 90% of
patients after valve implantation had SWI lesions.15 However,
this study was underpowered to detect a signiﬁcant difference
of SWI lesions between patients with mHV and bHV.31,32 The
occurrence of SWI lesions very early after implantation in 2
prospective studies15,25 challenges the hypothesis that those
lesions are caused by degenerative metal abrasion, because
the MRI was performed only days after the implantation and
modern mHV are no longer composed of metal, but mainly
carbon. This further weakens the hypothesis of degenerative
metallic abrasion as a main reason for SWI lesions seen in
patients with aHV and spotlights CPB as the main risk factor
for SWI occurrence. Autopsy studies are warranted to identify
the true pathophysiological cause of SWI lesions in patients
with CPB exposure.
The small increase in patients receiving off-pump tran-
scatheter aortic valve implantations in our cohort and in
patients without SWI lesions postinterventionally might reﬂect
non-CPB-related SWI lesion formation, underlying vascular
risk factors or normal aging. However, this remains to be
proven since to our knowledge no studies with systematic
pre- and postinterventional SWI sequences have been
published in transcatheter aortic valve implantation patients.
Studies with pre- and postinterventional SWI sequences have
been performed, but results were published only for diffusion-
weighted imaging lesions.33
Because in our cohort we had additional follow-up MRIs
available in several patients, we could show that the SWI
lesion count remained stable over time in the majority of
them. Long-term studies should clarify whether aHV represent
a risk factor for ongoing excessive SWI lesion appearance.
Clinical Implications of SWI Lesions in Patients
With aHV Related to CAA
In a relevant percentage of this aHV patient cohort, postin-
terventional distribution of SWI lesions was suggestive of
CAA, with 23.9% of patients fulﬁlling the criteria of possible or
probable CAA according to the modiﬁed Boston criteria
postinterventionally. Interestingly, only 16% of those patients
had superﬁcial siderosis, whereas in true CAA superﬁcial
siderosis was more frequent than CMBs16 and represented an
additional risk factor for incident ICH and poor functional
outcome.34 Of these patients, 9 had an available preinterven-
tional MRI. In 4 patients without preinterventional SWI lesions,
3 fulﬁlled the criteria for probable CAA and 1 for possible CAA
postinterventionally. Three patients already fulﬁlled the crite-
ria for probable CAA before the intervention, whereas in 2 the
rating changed from possible to probable.
Because CMBs are increasingly considered in guiding
treatment decisions for intravenous thrombolysis17,35 or
anticoagulation,18 we hence question whether the SWI lesions
seen with CPB share the same pathophysiological features
and long-term bleeding risk as CMBs seen with CAA or
classical vascular risk factors. The fact that age was inversely
associated with SWI lesion count also on multivariate analysis
further calls into question the comparability of SWI lesions
seen with aHV and true CMBs, which are known to be strongly
associated with age.20,21
In our cohort, several patients showed additional very
small SWI lesions not commonly seen with CAA. However,
the size of a SWI lesion depends on many technical factors
such as magnetic ﬁeld strength and sequence. Thus, we
propose that future studies should include size, distribution,
and shape of SWI lesions in attempts to differentiate CAA-
and aHV-associated lesions using standardized MRI
sequence protocols.
Limitations
This is a single-center retrospective study, which has inherent
limitations. Intervals between valve implantation and MRI
scans were heterogeneous and preprocedure MRI scans were
available in only 25/155 (16%) of patients. Indications for
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cerebral MRI were neurological symptoms in 87% of patients
leading to a population bias, so generalization of our ﬁndings
to aHV patients without clinical indications for cerebral MRI is
not possible. The goodness of ﬁt of our multilinear logistic
regression was insufﬁcient (R2=0.423), indicating further
neglected factors besides CPB contributing to SWI lesion
formation. Data on extracorporeal membrane oxygenation
before or after implantation were not available, which might
have been used more often in patients with long CPB times.
Furthermore, CPB reﬂects the complexity of the procedure
and many other confounding factors; hence it might only be a
surrogate parameter of SWI lesion formation rather than its
pathophysiological explanation.
Conclusions
SWI lesions in patients with aHV were frequent and showed a
temporal association with the implantation. SWI lesions
associated with cardiac procedures can mimic CAA, but
superﬁcial siderosis is seldom present in those patients.
Further research needs to clarify whether those lesions are
associated with intracranial hemorrhage after intravenous
thrombolysis or long-term anticoagulation. We propose that
until clinical suspicion for CAA is high or superﬁcial siderosis
present, SWI lesions in patients with CPB exposure should not
alter management. Autopsy studies are warranted to identify
the true pathophysiological cause of SWI lesions in patients
with aHV. Prospective studies should compare implantation
procedures with and without CPB and identify further factors
inﬂuencing SWI lesions formation during aHV implantation
(eg, maximum activated partial thromboplastin time or
speciﬁc CPB components).
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Table S1. Characteristics of Patients According to Use of Cardiopulmonary Bypass (CPB).  
 CPB yes (n=137) CPB no (n=18) P 
Baseline characteristics    
Age (years) 70 (IQR 57-77) 79 (IQR 74-82) <0.001 
Female sex 37 (27.0%) 7 (38.9%) 0.404 
Risk factors     
Hypertension 98 (72.6%) 17 (94.4%) 0.045 
Smoking 36 (26.7%) 8 (44.4%) 0.164 
Diabetes 24 (17.8%) 8 (44.4%) 0.026 
eGFR 77 (IQR 60-90) 58 (IQR 36-75) 0.005 
BMIw 26.9 (IQR 24.2-30.0) 28.4 (IQR 24.4-32.1) 0.388 
Surgery     
Mechanical Valve 58 (42.3%) 0 (0%) <0.001 
Ascendens replacement 34 (24.8%) 0 (0%) 0.013 
PFO/ASD closure 4 (2.9%) 1 (5.6%) 0.465 
Days in ICU 1 (IQR 1-2) 0 (IQR 0-1) <0.001 
Medication    
ASS  78 (56.9%) 10 (55.6%) 1.000 
Clopidogrel 10 (7.3%) 5 (27.8%) 0.017 
VKA 70 (51.1%) 3 (16.7%) 0.006 
NOAC 7 (5.1%) 5 (27.8%) 0.006 
OAC, any 77 (56.2%) 8 (44.4%) 0.451 
Statin, any 68 (49.6%) 11 (64.7%) 0.307 
Imaging    
Number of SWI lesions on 
1st postoperative scan 
7 (IQR 3-13.5) 1.5 (IQR 1-4) <0.001 
 
CPB: Cardiopulmonary bypass, BMI: body mass index (kg/m2), eGFR: estimated glomerular filtration rate (ml/min), PFO: 
persisting foramen ovale; ASD: atrial septal defect; ICU: intensive care unit; ASS: acetylic salicylic acid; VKA: vitamin k 
antagonists, NOAC: non vitamin k antagonist oral anticoagulants, OAC: oral anticoagulation, SWI: susceptibility weighted 
imaging.  
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Table S2. Characteristics of Patients According to Valve Type. 
 Biological valve 
(N=97) 
Mechanical Valve 
(N=58) 
P 
 
 
Baseline characteristics    
Age (years) 74 (IQR 70-79) 57 (IQR 48-64) <0.001 
Female sex 30 (30.9%) 14 (24.1%) 0.462 
Risk factors     
BMI 27.7 (IQR 24.4-30.9) 26.1 (IQR 23.1-29.3) 0.035 
Hypertension 80 (83.8%) 35 (61.4%) 0.004 
Smoking 29 (30.2%) 15 (26.3%) 0.731 
Diabetes 28 (29.2%) 4 (7.0%) 0.001 
eGFR 71 (IQR 52-90) 83 (IQR 60-90) 0.051 
Surgery     
Cardiopulmonary bypass 
(CPB) used 
79 (81.4%) 58 (100%) <0.001 
CPB duration, minutes 83 (IQR 48-116) 128 (IQR 79-183) <0.001 
Ascendens replacement 14 (14.4%) 20 (34.5%) 0.005 
PFO/ASD closure 4 (4.1%) 1 (1.7%) 0.651 
Days in ICU 1 (IQR 1.0-1.25) 1 (IQR 1-2) 0.003 
Medication    
ASS  67 (69.1%) 21 (36.2%) <0.001 
Clopidogrel 11 (11.3%) 4 (6.9%) 0.416 
VKA 21 (21.6%) 52 (89.7%) <0.001 
NOAC 10 (10.3%) 2 (3.4%) 0.213 
OAC, any 31 (32.0%) 54 (93.1%) <0.001 
Statin, any 58 (60.4%) 21 (36.2%) 0.005 
Imaging    
Number of SWI lesions on 
1st postinterventional scan 
5 (IQR 2-9) 9 (IQR 4-20) 0.001 
 
BMI: body mass index (kg/m2), eGFR: estimated glomerular filtration rate (ml/min), PFO: persisting foramen ovale; ASD: 
atrial septal defect; ICU: intensive care unit; ASS: acetylic salicylic acid; VKA: vitamin k antagonists, NOAC: non vitamin k 
antagonist oral anticoagulants, OAC: oral anticoagulation, SWI: susceptibility weighted imaging. 
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Figure S1a. Distribution of SWI lesions on 1st postinterventional MRI scan in patients 
receiving a mechanical heart valve (N=58). 
 
 
Figure S1b. Distribution of SWI lesions on 1st postinterventional MRI scan in patients 
receiving a biological heart valve (N=97). 
 
 
SWI: susceptibility weighted imaging 
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Figure S2. Distribution of SWI lesions on 1st postinterventional MRI scan in patients 
according to use of cardiopulmonary bypass.  
 
 
 
 
 
 
 
SWI: susceptibility weighted imaging 
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Figure S3. Distribution of SWI lesions on 1st postinterventional MRI scan in patients 
according to type of valve implanted.  
 
 
 
 
SWI: susceptibility weighted imaging 
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Figure S4. Scatter plot of SWI lesion count according to time of cardiopulmonary bypass.  
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Figure S5a. Pie chart of valve type in patients on cardiopulmonary bypass.  
 
 
 
Figure S5B. Pie chart of valve type in patients off cardiopulmonary bypass.  
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Figure S6. Location of SWI lesions according to valve type.  
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Figure S7. Location of SWI lesions according to use of cardiopulmonary bypass.  
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